Top > Search of International Patents > PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF

PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF

Foreign code F170009073
File No. (S2015-1988-N26)
Posted date May 29, 2017
Country WIPO
International application number 2016JP078607
International publication number WO 2017057450
Date of international filing Sep 28, 2016
Date of international publication Apr 6, 2017
Priority data
  • P2015-196227 (Oct 1, 2015) JP
Title PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF
Abstract The present invention provides a novel peptide that specifically accumulates in biliary tract cancer. The peptide according to the present invention is (a) a peptide having an amino acid sequence containing a sequence represented by SEQ ID NO. 1, or (b) a peptide having an amino acid sequence containing a sequence having an identity of 60% or more with respect to the sequence represented by SEQ ID NO. 1, and specifically accumulates in biliary tract cancer.
Outline of related art and contending technology BACKGROUND ART
Biliary cancer, cholangiocarcinoma, gallbladder cancer, and duodenal cancer cancer composed of the nipple portion. Gall bladder cancer and bile duct cancer in Japan is the number of deaths, about 8,900 male person 2013 years, about 9,300 female person. Gall bladder cancer and cholangiocarcinoma (national estimate) number is suffering from, 2010 years, about 11,300 male and female example example about 11,300, 2% and 3% each occupy the entire number of suffering from cancer. In addition, in the gall bladder and bile duct cancer patients, surgical procedures may be applied between about 20% and, further, after surgery 30% years survival rate of from about 5 in. Biliary cancer is, almost no subjective symptoms at an early, jaundice, white stool, urine jaundice, abdominal pain and the like at the point of the appearance of symptoms which has proceeded to some extent, is found at an early stage is important in the treatment. It should be noted that, in the present specification histopathologically biliary bile duct cancer is adenocarcinoma of epithelial origin, gland squamous cell carcinoma, intrahepatic bile duct cell carcinoma which includes the.
Biliary cancer (in particular, in liver or extra-hepatic bile duct epithelial-derived cancer) of the test and diagnosis method, blood biochemical tests, abdominal ultrasound, abdominal contrast CT inspection, endoscopic retrograde to insert the angiographic (ERCP: endoscopic retrograde cholangiopancreatography), FDG-PET and the like inspection (Fluorodeoxy glucose-Positron Emission Tomography).
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, requires the delivery of drug target selection to the treatment of malignant tumors (Drag Delivery System) apply the tool DDS, cause serious side effects in that it is difficult to use. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, or an existing blood vessel endothelial cells of angiogenic blood vessels (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, without a simultaneous combination alone in the form of other pharmaceutical and or imaging agents have been applied as DDS (for example, see Patent Document 1.).
Scope of claims (In Japanese)[請求項1]
以下の(a)又は(b)のペプチド。
(a)配列番号1で表される配列を含むアミノ酸配列からなるペプチド、
(b)配列番号1で表される配列と同一性が60%以上である配列を含むアミノ酸配列からなり、且つ、胆道癌に特異的な集積性を有するペプチド
[請求項2]
環状構造である請求項1に記載のペプチド。
[請求項3]
さらに、N末端及びC末端にシステイン残基を備える請求項1又は2に記載のペプチド。
[請求項4]
D体アミノ酸に置換したRetro-Inverso型である請求項1~3のいずれか一項に記載のペプチド。
[請求項5]
請求項1~4のいずれか一項に記載のペプチドをコードすることを特徴とする核酸。
[請求項6]
請求項5に記載の核酸を含むことを特徴とするベクター。
[請求項7]
請求項1~4のいずれか一項に記載のペプチドを含むことを特徴とするキャリア。
[請求項8]
さらに、標識物質又は修飾物質を備える請求項7に記載のキャリア。
[請求項9]
前記標識物質が、安定同位体、放射性同位体又は蛍光物質である請求項8に記載のキャリア。
[請求項10]
前記修飾物質が、糖鎖又はポリエチレングリコールである請求項8又は9に記載のキャリア。
[請求項11]
請求項7~10のいずれか一項に記載のキャリアと生理活性物質とを備えることを特徴とする医薬組成物。
[請求項12]
胆道癌治療用又は診断用である、請求項11に記載の医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • KONDO Eisaku
  • SAITO Ken
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close